Investing in MedTech
Invest in cutting-edge medical technologies that could revolutionise healthcare practices and improve patient outcomes.
Cookies help to improve your website experience and provide secure services. Some cookies are essential for security and login functionalities, others enable easier use and convenient support. You can revoke your decision at any time.
Invest in cutting-edge medical technologies that could revolutionise healthcare practices and improve patient outcomes.
Investing in medtech allows individuals to contribute to the improvement of healthcare by supporting companies that aim to enhance diagnostic accuracy, treatment effectiveness, and patient care. Successful startups may attract partnerships or collaborations with established healthcare companies, providing further opportunities for growth and development.
Many investors are increasingly interested in impact investing, where financial returns are aligned with positive social or environmental outcomes. Investing in MedTech projects that aim to improve healthcare outcomes can be seen as a form of impact investing.
Read our latest blogpost on the topic: 8 reasons for the success of Finnish MedTech companies.
Koite Health has developed and commercially launched Lumoral, which kills 99.99% of the harmful bacteria in the mouth. The entire Lumoral treatment process can be done at home and takes less than 15 minutes.
Since the market entry in 2020, more than 10,000 Lumorals have been sold and Koite Health has doubled its revenues every year. The technology is patented and is based on strong scientific evidence and support.
Koite Health is now growing globally in the €31bn home dental care market.
Monidor offers remote monitoring software and devices to detect problems earlier, release more time to care and avoid risk of mistakes. With its service the company helps hospitals improve patient safety, save nurses' and doctors' time and improve workflows.
The market for remote infusion therapy and key vital signs monitoring is experiencing rapid growth. According to global market forecasts, the industry is projected to achieve an impressive annual growth rate (CAGR) of approximately 17.6% between 2023 and 2030.
Blood vessel occlusions occur at the vascular injury sites and play a key role in many diseases, inc. diabetes, COVID-19/sepsis and peripheral artery disease. Aplagon’s product APAC uniquely prevents blood vessel occlusions at vascular injury sites.
Please note
Liquidity in investments can vary and it's important to note that investments come with risks. Not all projects may succeed. Medtech companies can face challenges related to regulatory approval, market adoption, and competition. Investors should understand the risks involved, and be aware of the long development timelines typical in the medtech industry. While investing in early-stage companies is risky, successful medtech projects can offer substantial returns on investment.
Potential for high returns
Impact on healthcare
Long-term investment
We believe that our world needs change. Change towards a more sustainable, equitable and responsible world. But it will not change by itself. We believe that meaningful progress comes from entrepreneurial people who challenge the existing reality. What if we gave everyone the power to create change? The power to decide what kind of future they want to create. The power to choose companies that they believe can make that future a reality.
